Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Inclusion Criteria: * age ≥ 18 years * Eastern Cooperative Oncology Group performance status of 0-1 * clinical or pathological diagnosis of HCC * with unresectable locally advanced or oligometastatic HCC (metastatic lesions ≤ 5, metastatic organs ≤ 3, may involve extrahepatic lymph nodes or distant organs apart from brain) * at least one measurable lesion according to mRECIST criteria * all lesions could be included in radiation target volume * Child-Pugh A or B (7 scores) liver function * patients are allowed to receive systemic therapy previously other than tislelizumab plus regorafenib * adequate hematological and renal function * life expectancy ≥ 3 months； * willing to participate in the study and give written informed consent Exclusion Criteria: * a history of liver transplantation * with severe cirrhosis complications, including a history of esophagogastric variceal bleeding, hepatic encephalopathy, and massive ascites * with active autoimmune diseases or a history of autoimmune disease * with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) * allergic to the ingredient of tislelizumab or regorafenib * with recurrent lesions treated with radiotherapy previously * prescribed radiation does could not be delivered due to dose limits to organs at risk (OAR) * intolerable to radiation or systemic treatment because of cardiac insufficiency, uncontrolled high blood pressure * a history of other malignancies, except cured basal cell or squamous cell skin cancer or carcinoma in situ of the cervix